Literature DB >> 30996068

Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer.

Ana Pissarra1, Mariana Malheiro1, Leonor Vasconcelos Matos1, Ana Neto Plácido1.   

Abstract

Colorectal cancer is the third most common cancer in men and the second in women. The standard chemotherapy regiment in stage III colon cancer is based in oxaliplatin. The most common side effects include neutropenia, peripheral neuropathy, vomiting and diarrhoea. Rhabdomyolysis due to oxaliplatin is rare, and there are no established guidelines for managing this adverse event. This report describes a case of a 52-year-old man, with a resected stage III colon cancer that started postoperative adjuvant chemotherapy with capecitabine plus oxaliplatin. After the second cycle, the patient developed distal muscle pain and weakness, with a total inability to walk. Blood tests showed an elevated creatine kinase and renal injury. Severe drug-related rhabdomyolysis was diagnosed. The goal of this case report is to discuss the side effect of adjuvant chemotherapy, given its rarity and severity. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; chemotherapy; colon cancer; musculoskeletal and joint disorders; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2019        PMID: 30996068      PMCID: PMC6506057          DOI: 10.1136/bcr-2018-228673

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  Oxaliplatin: mechanism of action and antineoplastic activity.

Authors:  E Raymond; S Faivre; J M Woynarowski; S G Chaney
Journal:  Semin Oncol       Date:  1998-04       Impact factor: 4.929

2.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

3.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Authors:  Daniel J Sargent; Smitha Patiyil; Greg Yothers; Daniel G Haller; Richard Gray; Jacqueline Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; David Kerr; Erin Green; Harry S Wieand; Richard M Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

4.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Authors:  J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

5.  Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.

Authors:  Hans-Joachim Schmoll; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Silke Hoersch; Karen Rittweger; Daniel G Haller
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

6.  Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.

Authors:  Ramesh K Ramanathan; Jeffery W Clark; Nancy E Kemeny; Heinz-Josef Lenz; Kim O Gococo; Daniel G Haller; Edith P Mitchell; Carl G Kardinal
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

7.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel Sargent; Alberto Sobrero; Axel Grothey; Michael J O'Connell; Marc Buyse; Thierry Andre; Yan Zheng; Erin Green; Roberto Labianca; Chris O'Callaghan; Jean Francois Seitz; Guido Francini; Daniel Haller; Greg Yothers; Richard Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

10.  Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature.

Authors:  Mor Moskovitz; Mira Wollner; Nissim Haim
Journal:  Case Rep Oncol Med       Date:  2015-05-10
View more
  1 in total

1.  Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report.

Authors:  Akari Utsumi; Yuri Goto; Takaaki Suzuki; Chiaki Imai; Shinichiro Matsui; Emiko Sakaida; Itsuko Ishii
Journal:  J Pharm Health Care Sci       Date:  2022-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.